TG Therapeutics Inc (TGTX)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 43% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Session momentumUp 2.0% on the session+5
- 12-month trend+62% over the past year+6
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityRevenue growing 76% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst is **none** — these headlines are general sector and market roundups that don't specifically concern TG Therapeutics, so there's no company-specific driver here. Continuation likelihood is **low-to-moderate (~30–40%)**, since any near-term move would likely reflect broad biotech/market sentiment rather than a TGTX-specific catalyst. Informational only — not financial advice.
- Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour InYahoo · 2026-10-19
- Apple, Salesforce Lead Five Stocks Near Buy PointsYahoo · 2026-10-17
- Meta, Tesla, SpaceX Take Center Stage As Earnings Season Kicks Into High Gear. Everything You Need To Know.Yahoo · 2026-10-16
- Humana's CenterWell Expansion Gets a Boost From BlackRock's CapitalYahoo · 2026-10-14
- Here's How Quest Diagnostics Is Placed Ahead of Q3 EarningsYahoo · 2026-10-14
Any AI summary is an interpretation of public news, not advice or a price target.